Influence of CCR5 δ32 polymorphism on multiple sclerosis susceptibility and disease course

Multiple Sclerosis

Volumn 10, Issue 2, 2004, Pages 149-152

  Silversides, J A ^a   Heggarty, S V ^b   McDonnell, G V ^c   Hawkins, S A ^a   Graham, Colin A ^b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b BELFAST CITY HOSPITAL   (United Kingdom)

^c ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

Autoimmunity; CCR5; Chemokine receptors; Chemokines; Human; Multiple sclerosis; Receptors

Indexed keywords

CHEMOKINE RECEPTOR CCR5;

ADULT; ALLELE; ARTICLE; CALCULATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; GENE DELETION; GENETIC ASSOCIATION; GENETIC CODE; GENETIC POLYMORPHISM; HEALTH STATUS; HEALTH SURVEY; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL SPECIALIST; MULTIPLE SCLEROSIS; ONSET AGE; OUTPATIENT DEPARTMENT; PHYSICAL DISABILITY; POPULATION RESEARCH; PROGNOSIS; RATING SCALE; STATISTICAL ANALYSIS; GENETIC PREDISPOSITION; GENETICS; PREVALENCE; UNITED KINGDOM;

ADULT; AGE OF ONSET; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NORTHERN IRELAND; POLYMORPHISM, GENETIC; PREVALENCE; RECEPTORS, CCR5;

EID: 3042741204     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458504ms994oa     Document Type: Article

References (23)

1. McDonnell GV, Hawkins SA. An epidemiologic study of multiple sclerosis in Northern Ireland. Neurology 1998; 50: 423-28.
2. Sadovnick AD, Armstrong H, Rice GPA, Bulman D, Hashimoto L, Paty DW et al. A population-based study of multiple sclerosis in twins: update. Ann Neurol. 1993; 33: 281-85.
3. Sawcer S, Jones HB, Feakes R, Gray J, Smaldon N, Chataway J et al. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nat Genet 1996; 13: 464-68.
4. The Multiple Sclerosis Genetics Group. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. Nat Genet 1996; 13: 469-71.
5. Ebers GC, Kukay K, Bulman DE, Sadovnick AD, Rice G et al. A full genome search in multiple sclerosis. Nat Genet 1996; 13: 472-76.
6. McDonnell GV, Mawhinney H, Graham CA, Hawkins SA, Middleton D. A study of the HLA DR region in clinical subgroups of multiple sclerosis and its influence on prognosis. J Neurol Sci 1999; 165: 77-83.
7. Cullen CG, Middleton D, Savage DA, Hawkins S. HLA-DR and -DQ genotyping in multiple sclerosis patients in Northern Ireland. Hum Immunol 1991; 30: 1-6.
8. Mahad DJ, Howell SJ, Woodroofe MN. Expression of chemokines in the CSF and correlation with clinical disease activity in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2002; 72: 498-502.
9. Miyagishi R, Kikuchi S, Fukazawa T, Tashiro K. Macrophage inflammatory protein-1α in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory diseases. J Neurol Sci 1995; 129: 223-27.
10. Sørensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999; 103: 807-15.
11. Simpson JE, Newcombe J, Cuzner ML, Woodroofe MN. Expression of monocyte chemoattractant protein-1 and other b-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J Neuroimmunol 1998; 84: 238-49.
12. + T cells are increased in multiple sclerosis and their ligands MIP-1α and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci USA 1999; 96: 6873-78.
13. Zang YCQ, Samanta AK, Halder JB, Hong J, Tejada-Simon MV, Rivera VM et al. Aberrant T cell migration toward RANTES and MIP-1α in patients with multiple sclerosis. Overexpression of chemokine receptor CCR5. Brain 2000; 123: 1874-82.
14. Dai Y, Xu C, Holmberg M, Oturai A, Fredrikson S, Sanberg-Wollheim M et al. Linkage analysis suggests region of a importance for multiple sclerosis in 3 p14-13. Revue Neurol 2000; 156: P123.
15. Bennetts BH, Teutsch SM, Buhler MM, Heard RNS, Stewart GJ. The CCR5 deletion mutation fails to protect against multiple sclerosis. Hum Immunol 1997; 58: 52-59.
16. Chataway J, Sawcer S, Feakes R, Coraddu F, Broadley S, Gray J et al. More evidence that founder effects exist in the European population. Eur J Hum Genet 1997; 7: 623-24.
17. Sellebjerg F, Madsen HO, Jensen CV, Jensen J, Garred J. CCR5 δ32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. J Neuroimmunol 2000; 102: 98-106.
18. Multiple Sclerosis Genetics Group. CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Immunogenetics 2000; 51: 281-88.
19. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 144-52.
20. Jeanpierre M. A rapid method for the purification of DNA from blood. Nucleic Acids Res 1987; 15: 961.
21. Benkirane M, Jin D-Y, Chun RF, Koup RA, Jeang K-T. Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by CCR5δ32. J Biol Chem 1997; 272: 30603-606.
22. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998; 392: 565-68.
23. Giovannoni G, Kieseier B, Hartung HP. Correlating immunological and magnetic resonance imaging markers of disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998; 64 Suppl: S31-36.